ProPhase Labs, Inc.

ProPhase Labs, Inc. (the “Company”) is unable, without unreasonable effort or expense, to timely file its Quarterly Report on Form 10-Q for the Quarter Ended June 30, 2026. The delay in filing is primarily due to the additional time required to complete the Company’s review procedures performed by the Company’s independent registered public accounting firm. The Company is working diligently with its auditors to finalize the financial statements and related disclosures

ProPhase Labs, Inc. (the “Company”) is unable, without unreasonable effort or expense, to timely file its Quarterly Report on Form 10-Q for the Quarter Ended March 31, 2026. The delay in filing is primarily due to the additional time required to complete the Company’s year-end financial reporting process and its Annual Report on Form 10-K, including the completion of the ongoing audit procedures performed by the Company’s independent registered public accounting firm. The Company is working diligently with its auditors to finalize the financial statements and related disclosures and will be filed following the Annual Report on Form 10-K when the Audit for the year ended December 31, 2025 is completed

ProPhase Labs, Inc. (the “Company”) is unable, without unreasonable effort or expense, to timely file its Annual Report on Form 10-K for the fiscal year ended December 31, 2025. The delay in filing is primarily due to the additional time required to complete the Company’s year-end financial reporting process, including the completion of the Company’s income tax provision and the ongoing audit procedures performed by the Company’s independent registered public accounting firm. The Company is working diligently with its auditors to finalize the financial statements and related disclosures and currently expects to file its Form 10-K within the fifteen-day extension period permitted under Rule 12b-25

ProPhase Labs, Inc. (the “Company”) is unable, without unreasonable effort or expense, to timely file with the Securities and Exchange Commission (the “SEC”) its Quarterly Report on Form 10-Q for the quarter ended September 30, 2025 (the “Form 10-Q”) due to the additional time required by the Company and its auditor to review and ensure the accuracy and completeness of the information to be included in the Form 10-Q. The Company expects to file the Form 10-Q no later than within the 5-day extension period provided by Rule 12b-25. Cautionary Statement Regarding Forward-Looking Statements This filing contains “forward-looking” statements within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995, including, but not limited to, statements regarding the expected timing of filing of its periodic reports. Forward-looking statements can be identified by words such as: “believe,” “may,” “will,” “potentially,” “estimate,” “continue,” “anticipate,” “intend,” “could,” “would,” “project,” “plan,” “expect” or the negative or plural of these words or similar expressions. These forward-looking statements include, but are not limited to, statements regarding our beliefs and expectations relating to the filing of the Form 10-Q and the results of the ongoing analysis of our financial statements. These forward-looking statements are not guarantees of future results and are subject to a number of risks and uncertainties, many of which are difficult to predict and beyond our control. Important factors that may cause actual results to differ materially from those in the forward-looking statements include, but are not limited to, a material delay in the Company’s financial reporting, including the possibility that the Company will not be able to file its Form 10-Q within the five-day extension permitted by the rules of the U.S. Securities and Exchange Commission

ProPhase Labs, Inc. (the “Company”) is unable, without unreasonable effort or expense, to timely file with the Securities and Exchange Commission (the “SEC”) its Quarterly Report on Form 10-Q for the quarter ended March 31, 2025 (the “Form 10-Q”) due to the additional time required by the Company’s new auditor to review and ensure the accuracy and completeness of the information to be included in the Form 10-Q. The Company expects to file the Form 10-Q no later than within the 5-day extension period provided by Rule 12b-25. Cautionary Statement Regarding Forward-Looking Statements This filing contains “forward-looking” statements within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995, including, but not limited to, statements regarding the expected timing of filing of its periodic reports. Forward-looking statements can be identified by words such as: “believe,” “may,” “will,” “potentially,” “estimate,” “continue,” “anticipate,” “intend,” “could,” “would,” “project,” “plan,” “expect” or the negative or plural of these words or similar expressions. These forward-looking statements include, but are not limited to, statements regarding our beliefs and expectations relating to the filing of the Form 10-Q and the results of the ongoing analysis of our financial statements. These forward-looking statements are not guarantees of future results and are subject to a number of risks and uncertainties, many of which are difficult to predict and beyond our control. Important factors that may cause actual results to differ materially from those in the forward-looking statements include, but are not limited to, a material delay in the Company’s financial reporting, including the possibility that the Company will not be able to file its Form 10-Q within the five-day extension permitted by the rules of the U.S. Securities and Exchange Commission

ProPhase Labs, Inc. (the “Company”) has experienced an unexpected delay in completing the necessary disclosures in connection with its Annual Report on Form 10-K for the fiscal year ended December 31, 2024 (the “Annual Report”). The Company was able to file its Form 10-K after 5:30 p.m. on March 31, 2025, but because it missed the 5:30 p.m. EDGAR filing deadline, the Annual Report is being posted on the Securities and Exchange Commission website as being filed on April 1, 2025. As a result of this delay, the Company was unable to file its Annual Report by the prescribed filing deadline March 31, 2025 without unreasonable effort or expense

ProPhase Labs, Inc. (the “Company”) is unable, without unreasonable effort or expense, to timely file with the Securities and Exchange Commission (the “SEC”) its Quarterly Report on Form 10-Q for the quarter ended September 30, 2024 (the “Form 10-Q”) due to the engagement of a new auditor as previously disclosed in the Company’s Current Report on Form 8-K filed with the SEC on October 18, 2024. This has necessitated additional time to ensure the accuracy and completeness of the information to be included in the Form 10-Q. The Company expects to file the Form 10-Q no later than within the 5-day extension period provided by Rule 12b-25

ProPhase Labs, Inc. (the “Company”) is unable, without unreasonable effort or expense, to timely file with the Securities and Exchange Commission its Quarterly Report on Form 10-Q for the quarter ended June 30, 2024 (the “Form 10-Q”) due to a recent information technology disruption related to a CrowdStrike incident in July 2024, which impacted the Company’s information technology, accounting, and reporting systems. This has necessitated additional time to ensure the accuracy and completeness of the information to be included in the Form 10-Q. The Company expects to file the Form 10-Q no later than within the 5-day extension period provided by Rule 12b-25

ProPhase Labs, Inc. (the “Company”) is unable to timely file with the Securities and Exchange Commission its Annual Report on Form 10-K for the year ended December 31, 2023 (the “Form 10-K”) without unreasonable effort or expense. As a first time accelerated filer, the Company is now subject to Section 404(b) of the Sarbanes-Oxley Act of 2002 and requires additional time to complete the assessment of the Company’s internal controls over financial reporting as of December 31, 2023. The Company expects to file the Form 10-K, including its audited financial statements for the year ended December 31, 2023, no later than within the 15-day extension period provided by Rule 12b-25